Wuhan YZY Biopharma Co Ltd

NEW
HKSE:02496 (China)   Ordinary Shares - Class H
HK$ 3.79 (-0.26%) Dec 13
At Loss
P/B:
13.54
Market Cap:
HK$ 734.69M ($ 94.49M)
Enterprise V:
HK$ 690.03M ($ 88.75M)
Volume:
-
Avg Vol (2M):
6.60K
Trade In:
Volume:
-
At Loss
Avg Vol (2M):
6.60K

Business Description

Description
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing a new class of medicines in respect to anti-tumor bispecific antibody. It generates the majority of its revenue from PRC.
Name Current Vs Industry Vs History
Cash-To-Debt 1.35
Equity-to-Asset 0.19
Debt-to-Equity 2.42
Debt-to-EBITDA -0.66
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 0.01
9-Day RSI 0.54
14-Day RSI 2.96
3-1 Month Momentum % -20.54
6-1 Month Momentum % -33.29
12-1 Month Momentum % -42.18

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.24
Quick Ratio 1.21
Cash Ratio 0.95

Dividend & Buy Back

Name Current Vs Industry Vs History
Shareholder Yield % -3.78
Name Current Vs Industry Vs History
ROE % -206.61
ROA % -65.4
ROIC % -85.72
ROC (Joel Greenblatt) % -366.75
ROCE % -165.87

Financials

HKSE:02496's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Wuhan YZY Biopharma Co Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil HK$)
EPS (TTM) (HK$) -1.024
Beta -
3-Year Sharpe Ratio -
3-Year Sortino Ratio -
Volatility % 33.47
14-Day RSI 2.96
14-Day ATR (HK$) 0.075921
20-Day SMA (HK$) 4.28
12-1 Month Momentum % -42.18
52-Week Range (HK$) 3.65 - 9.06
Shares Outstanding (Mil) 193.85

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Wuhan YZY Biopharma Co Ltd Filings

Filing Date Document Date Form
No Filing Data

Wuhan YZY Biopharma Co Ltd Stock Events

Financials Calendars
Event Date Price (HK$)
No Event Data

Wuhan YZY Biopharma Co Ltd Frequently Asked Questions

What is Wuhan YZY Biopharma Co Ltd(HKSE:02496)'s stock price today?
The current price of HKSE:02496 is HK$3.79. The 52 week high of HKSE:02496 is HK$9.06 and 52 week low is HK$3.65.
When is next earnings date of Wuhan YZY Biopharma Co Ltd(HKSE:02496)?
The next earnings date of Wuhan YZY Biopharma Co Ltd(HKSE:02496) is .
Does Wuhan YZY Biopharma Co Ltd(HKSE:02496) pay dividends? If so, how much?
Wuhan YZY Biopharma Co Ltd(HKSE:02496) does not pay dividend.

Press Release

Subject Date
No Press Release